Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

Phase 1/2 Completed 30 enrolled National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.

Timeline

Start: 2018-07-12
Primary completion: 2021-06-30
Completion: 2025-10-30

Publications

Chen TW, Hsu CL, Hong RL, Lee JC, Chang K, Yu CW, Chen SC, Guo JC, Chen ML, Hsu MC, Kung TF, Cheng AL, Yen CC. A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 Dec 1;28(23):5058-5065. doi: 10.1158/1078-0432.CCR-22-2092.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	1.1 mg/m2	—
Subject	Lenvatinib	Small molecule	14 mg	Oral

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

Summary

Timeline

Publications

Drugs

Indications